Rapivab: An Overview of Uses, Dosage, Demographic, Side Effects, Interactions, and Generic Options Introduction Rapivab (peramivir) is a prescription medication approved by the Food and Drug Administration (FDA) in December 2014 for the treatment of acute uncomplicated influenza in patients 2 years and older who have been symptomatic for no more than 2 days. It is an antiviral drug that belongs to the neuraminidase inhibitor class of medications and is administered intravenously. Uses Rapivab is used as a treatment for acute uncomplicated influenza caused by influenza A or B viruses. It works by inhibiting the activity of neuraminidase, an enzyme that is present on the surface of the influenza virus and is responsible for its release from infected cells. By preventing the release of the virus, Rapivab can reduce the spread of the infection and shorten the duration of symptoms. Dosage Rapivab is administered intravenously by a healthcare provider in a hospital or clinic setting. The recommended dosage for adults and pediatric patients 13 years and older is 600 mg, administered as a single dose over 15-30 minutes. For pediatric patients 2 years to less than 13 years of age, the recommended dosage is based on weight. The total dose is 12 mg/kg, with a maximum dose of 600 mg, administered as a single dose over 15-30 minutes. Demographic Rapivab is approved for use in patients 2 years and older who have been symptomatic for no more than 2 days. It is recommended for patients who are at high risk of influenza-related complications, including those with underlying medical conditions such as asthma, chronic lung disease, diabetes, heart disease, or obesity, or those who are pregnant or elderly. Side Effects The most common side effects of Rapivab are diarrhea, constipation, nausea, vomiting, and headache. Less common side effects include allergic reactions, including anaphylaxis, and neuropsychiatric events, including delirium and abnormal behavior. Interactions Rapivab may interact with other drugs, including antacids, which may reduce the absorption of Rapivab. Patients who are taking other medications should inform their healthcare provider before receiving Rapivab. Generic Options There are currently no generic options for Rapivab. However, the active ingredient, peramivir, is also available in a different formulation, as an oral suspension, under the brand name RAPIACTA. Conclusion Rapivab is a prescription medication used for the treatment of acute uncomplicated influenza in patients 2 years and older who have been symptomatic for no more than 2 days. It is administered intravenously in a hospital or clinic setting and is recommended for high-risk patients. The most common side effects of Rapivab are diarrhea, constipation, nausea, vomiting, and headache. Patients who are taking other medications should inform their healthcare provider before receiving Rapivab. While there are currently no generic options for Rapivab, the active ingredient, peramivir, is available in a different formulation, as an oral suspension, under the brand name RAPIACTA.